8-K current report · filed Oct 2, 2026

BioAge Labs, Inc. (BIOA) 8-K Current Report: October 2, 2026

Item 8.01BIOA overview

Short answer

BioAge Labs, Inc. (BIOA) filed an 8-K current report with the SEC on October 2, 2026 reporting Item 8.01 (Other Events). First participant dosed in QUELL-DME, advancing BGE-102 into a randomized Phase 2 diabetic macular edema study.

BioAge Labs, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • First participant dosed in QUELL-DME, advancing BGE-102 into a randomized Phase 2 diabetic macular edema study
  • Approximately 180 participants across three arms, testing BGE-102 monotherapy and combination use with anti-VEGF therapy
  • Primary endpoint: best-corrected visual acuity change at week 12 after once-daily 90 mg dosing
  • Topline results expected in the second half of 2027, a potential catalyst for BGE-102’s retinal disease strategy
  • Results may guide development in other NLRP3-driven diseases, including geographic atrophy, but remain subject to clinical and regulatory risk

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other BioAge Labs, Inc. 8-K filings

Get the next BIOA 8-K as it lands

Follow BIOA for push alerts, or ask the research agent what this filing means.